Oct 2010

Company is awarded two grants by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of the company's two leading diagnostic tests in the pipeline, CT-VALA and CT-CYP3.
The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.

July 2010

Company 'graduates' from the Los Angeles Business Technology Center Incubator program and moves to new office in the Gateway Metro Center, Pasadena

June 2010

CTL signs a collaborative agreement with C3 Research Associates for Clinical Trial Services

Mar 2010

Company begins discussions for a Cooperative Research And Development Agreement (CRADA) with the National Cancer Institute (NCI) for development of fully human monoclonal antibodies

Sep 2009

FDA begins review of Company's Pre-IDE for CT-VALA genotyping Test Kit.

July 2009

Company submits a Pre-IDE application to the Food and Drug Administration (FDA) for Breast cancer biomarker for use as a chemotherapeutic response predictor

Dec 2008

Five Predictive Biomarkers for Breast, Ovarian and Prostate Cancers in-licensed from the NIH

May 2008

Company begins talks with NIH scientists for licensing of monoclonal antibody candidates

Apr 2008

NIH Prostate Cancer Biomarker licensing process initiated

Dec 2007

Licensing process initiated for Ovarian cancer biomarkers developed at the National Institutes of Health (NIH)

Dec 2005

Company receives a $100,000.00 startup loan from the Los Angeles County Community Development Commission

Apr 2004

Company approved for Los Angeles County Community Development Commission (CDC), Economic Development Division's Business Incubator Program and opened office at the County sponsored Los Angeles Business Technology Center (LA-BTC)